From genotype to outcomes: Real-world evidence in glomerular diseases

This presentation highlights real-world evidence from RenasightIQ to demonstrate how integrated clinical and genetic data are transforming risk stratification and treatment optimization in glomerular disease. With focused insights from genetic ancestry, we will examine how genetic drivers influence disease trajectory and therapeutic response. The session will also review real-world treatment effects of steroids/immunosuppression, ACE inhibitors/ARBs, and SGLT2 inhibitors. Together, these findings underscore how precision medicine approaches can improve prognostic clarity, guide treatment decisions, and drive better patient outcomes.